H.C. Wainwright Keeps Their Buy Rating on Albireo Pharma Inc (ALBO)

By Ryan Adsit

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma Inc (ALBOResearch Report) today and set a price target of $62. The company’s shares closed yesterday at $31.88.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.8% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Albireo Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $60.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $38.69 and a one-year low of $19.10. Currently, Albireo Pharma Inc has an average volume of 65.31K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384.